The eighth contract with the pharmaceutical company Valneva was approved by European Commission, with a view to purchasing its potential COVID-19 vaccine. The contract with Valneva provides for the possibility for all EU Member States to buy almost 27 million installments in 2022. It also includes the ability to customize the vaccine to new variants and for Member States to place further orders for up to 33 million additional vaccines by 2023.
The contract with Valneva is added to an already secured wide portfolio of vaccines to be produced in Europe, including contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna and Novavax Commission. This diversified portfolio of vaccines will ensure that Europe is well prepared for vaccination, once the vaccines is safe and effective. Member States could decide to donate the vaccine to low- and middle-income countries or redirect it to other European countries.
Ursula von der Leyen: The pandemic is not over
The President of the European Commission Ursula von der Leyen stressed that “the contract allows the vaccine to be adapted to new variants. Our extensive portfolio will help us combat COVID and its variants in Europe and beyond. The pandemic is not over. “Everyone who can should be vaccinated,” according to the APE-MPE correspondent in Brussels.
THE Stella Kyriakidou, The Commissioner for Health and Food Safety, said: “Our EU vaccine strategy continues to work, at a time when COVID-19 cases are unfortunately rising again across the EU. The Valneva vaccine adds another option in our wide portfolio, after proving to be safe and effective by the European Medicines Agency. “We continue to support the Member States in their vaccination efforts and the message remains the same: trust science and vaccinate, vaccinate, vaccinate.”
The European Commission presented on 17 June 2020 a European strategy to accelerate the development, manufacture and development of effective and safe vaccines against COVID-19. In return for the right to purchase a certain number of vaccine installments over a given period of time, the Commission finances part of the initial costs borne by vaccine producers in the form of advance payment agreements.
Taking into account the current and new variants of SARS-CoV-2, the Commission and the Member States are negotiating new agreements with companies that will allow the purchase of rapidly adapting vaccines in sufficient quantities to enhance and extend immunity.
To purchase the new vaccines, Member States can use REACT-EU, one of the largest Next Generation EU programs that continues and expands crisis response measures.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
